Brian M. Slomovitz, MD

Brian Slomovitz, MD, discusses the importance of education, prevention, and research in the context of gynecologic cancer awareness month.

Brian Slomovitz, MD, MS, FACOG, presents the study design, rationale, and primary endpoints of ENGOT-EN20/GOG-3083/XPORT-EC-042, which will be evaluating the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer.

Brian M. Slomovitz, MD, discusses the phase 3 DUO-E and AtTEnd trials investigating the use immunotherapy in endometrial cancer, as presented at the 2023 ESMO Congress.

Brian Slomovitz, MD, provides a look at an upcoming Rapid Readout program looking at the results of a phase 3 study of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Brian M. Slomovitz, MD, discusses the optimal role for PARP inhibition in patients with ovarian cancer, highlighting its efficacy in those harboring BRCA mutations.

Brian M. Slomovitz, MD, discusses the classification of molecular subtypes to guide treatment and care in endometrial cancers.

Brian M. Slomovitz, MD, discusses the evaluation of letrozole and ribociclib from the phase 2 GOG 3026 trial in recurrent low-grade serous ovarian carcinoma.

Brian M. Slomovitz, MD, discusses sequencing strategies for endometrial cancer.

Brian M. Slomovitz, MD, discusses the importance of developing sequencing strategies in endometrial cancer treatment.

Brian M. Slomovitz, MD, discusses sequencing strategies in endometrial cancer.